EMA/PE/0000232757 - paediatric investigation plan

sonelokimab

Key facts

• Active substance:
  sonelokimab
• Therapeutic area:
  Musculoskeletal and connective tissue disorders
• Decision number:
  EMA/PE/0000232757
• PIP number:
  EMA/PE/0000232757
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Psoriatic arthritis
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  15/04/2025
• Compliance check done:
  Ne

Decision

EMA/PE/0000232757 : EMA decision of 15 April 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sonelokimab

Adopted Reference Number: EMADOC-1700519818-2039189